Robert Lisicki brings over 25 years of experience in the pharma/biotech sector, most recently Robert was CEO and Board Members at InCarda Therapeutics. Prior to that he was the Chief Commercial Officer of Arena Pharmaceuticals, where he provided global visionary leadership for the $6.7 billion growth-stage biopharmaceutical company through their acquisition by Pfizer in March 2022. During his time as Chief Commercial Officer at Arena Pharmaceuticals, Lisicki had a leadership role in more than $8 billion in M&A activities. He regularly interacted with FDA, EMA, and PDMA on study and protocol designs. Prior to Arena, Lisicki was Vice President, General Manager of Inflammation & Immunology and Cardiovascular at Regeneron Pharmaceuticals, where he was responsible for both commercial and development stage efforts. From 2014 through 2018, Lisicki was Senior Vice President and Chief Customer Officer of Daichii-Sanyko, where he managed the successful global product launches in Cardiovascular and successful U.S. development in Pain and Oncology. From 2005 through 2014, he held key global roles with Amgen. Lisicki earned his BS in Finance and Economics from State University of New York at Albany.